

Kathrin Brockmann

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5991988/publications.pdf>

Version: 2024-02-01

74
papers

5,029
citations

159525

30
h-index

106281

65
g-index

79
all docs

79
docs citations

79
times ranked

6810
citing authors

#	ARTICLE	IF	CITATIONS
1	Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. <i>Lancet Neurology</i> , The, 2019, 18, 1091-1102.	4.9	1,414
2	A Multicenter Study of Glucocerebrosidase Mutations in Dementia With Lewy Bodies. <i>JAMA Neurology</i> , 2013, 70, 727.	4.5	374
3	Excessive burden of lysosomal storage disorder gene variants in Parkinson's disease. <i>Brain</i> , 2017, 140, 3191-3203.	3.7	323
4	<i>GBA</i> -associated Parkinson's disease: Reduced survival and more rapid progression in a prospective longitudinal study. <i>Movement Disorders</i> , 2015, 30, 407-411.	2.2	214
5	Genetic modifiers of risk and age at onset in <i>GBA</i> associated Parkinson's disease and Lewy body dementia. <i>Brain</i> , 2020, 143, 234-248.	3.7	149
6	Gait analysis with wearables predicts conversion to Parkinson disease. <i>Annals of Neurology</i> , 2019, 86, 357-367.	2.8	137
7	Arm swing as a potential new prodromal marker of Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 1527-1534.	2.2	136
8	Penetrance estimate of <i>LRRK2</i> p.G2019S mutation in individuals of non-Ashkenazi Jewish ancestry. <i>Movement Disorders</i> , 2017, 32, 1432-1438.	2.2	126
9	A pathway-based analysis provides additional support for an immune-related genetic susceptibility to Parkinson's disease. <i>Human Molecular Genetics</i> , 2013, 22, 1039-1049.	1.4	122
10	Enlarged hyperechogenic substantia nigra as a risk marker for Parkinson's disease. <i>Movement Disorders</i> , 2013, 28, 216-219.	2.2	112
11	Distinct metabolomic signature in cerebrospinal fluid in early parkinson's disease. <i>Movement Disorders</i> , 2017, 32, 1401-1408.	2.2	91
12	Cognitive changes in prodromal Parkinson's disease: A review. <i>Movement Disorders</i> , 2017, 32, 1655-1666.	2.2	82
13	Poor Trail Making Test Performance Is Directly Associated with Altered Dual Task Prioritization in the Elderly – Baseline Results from the TREND Study. <i>PLoS ONE</i> , 2011, 6, e27831.	1.1	78
14	Metformin reverses TRAP1 mutation-associated alterations in mitochondrial function in Parkinson's disease. <i>Brain</i> , 2017, 140, 2444-2459.	3.7	76
15	Application of the movement disorder society prodromal Parkinson's disease research criteria in 2 independent prospective cohorts. <i>Movement Disorders</i> , 2017, 32, 1025-1034.	2.2	75
16	The endocytic membrane trafficking pathway plays a major role in the risk of Parkinson's disease. <i>Movement Disorders</i> , 2019, 34, 460-468.	2.2	66
17	Clinical and brain imaging characteristics in leucine-rich repeat kinase 2-associated PD and asymptomatic mutation carriers. <i>Movement Disorders</i> , 2011, 26, 2335-2342.	2.2	65
18	Serum neurofilament light is increased in multiple system atrophy of cerebellar type and in repeat-expansion spinocerebellar ataxias: a pilot study. <i>Journal of Neurology</i> , 2018, 265, 1618-1624.	1.8	58

#	ARTICLE	IF	CITATIONS
19	Inflammatory profile in LRRK2-associated prodromal and clinical PD. <i>Journal of Neuroinflammation</i> , 2016, 13, 122.	3.1	57
20	Penetrance of Parkinson's Disease in <i>LRRK2</i> p.G2019S Carriers Is Modified by a Polygenic Risk Score. <i>Movement Disorders</i> , 2020, 35, 774-780.	2.2	57
21	Leucine-rich repeat kinase 2 functionally interacts with microtubules and kinase-dependently modulates cell migration. <i>Neurobiology of Disease</i> , 2013, 54, 280-288.	2.1	52
22	Association between CSF alpha-synuclein seeding activity and genetic status in Parkinson's disease and dementia with Lewy bodies. <i>Acta Neuropathologica Communications</i> , 2021, 9, 175.	2.4	49
23	<i>α</i> -Synuclein in Plasma-Derived Extracellular Vesicles Is a Potential Biomarker of Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 2508-2518.	2.2	47
24	Finding genetically-supported drug targets for Parkinson's disease using Mendelian randomization of the druggable genome. <i>Nature Communications</i> , 2021, 12, 7342.	5.8	44
25	Insulin sensitivity predicts cognitive decline in individuals with prediabetes. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e001741.	1.2	42
26	Identification of sixteen novel candidate genes for late onset Parkinson's disease. <i>Molecular Neurodegeneration</i> , 2021, 16, 35.	4.4	41
27	Gut Microbiome Signatures of Risk and Prodromal Markers of Parkinson Disease. <i>Annals of Neurology</i> , 2021, 90, E1-E12.	2.8	41
28	<i>GBA</i> -associated PD. <i>Neurology</i> , 2012, 79, 213-220.	1.5	40
29	The Mutation Matters: CSF Profiles of <i>GCase</i> , Sphingolipids, <i>α</i> -Synuclein in <i>PD_{GBA}</i> . <i>Movement Disorders</i> , 2021, 36, 1216-1228.	2.2	40
30	SNCA: Major genetic modifier of age at onset of Parkinson's disease. <i>Movement Disorders</i> , 2013, 28, 1217-1221.	2.2	36
31	The significance of <i>GBA</i> for Parkinson's disease. <i>Journal of Inherited Metabolic Disease</i> , 2014, 37, 643-648.	1.7	36
32	CSF NFL in a Longitudinally Assessed <i>PD</i> Cohort: Age Effects and Cognitive Trajectories. <i>Movement Disorders</i> , 2020, 35, 1138-1144.	2.2	36
33	Soluble <i>CD163</i> Changes Indicate Monocyte Association With Cognitive Deficits in Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 963-976.	2.2	35
34	Broad clinical phenotype in Parkinsonism associated with a base pair deletion in <i>RAB39B</i> and additional <i>POLG</i> variant. <i>Parkinsonism and Related Disorders</i> , 2016, 31, 148-150.	1.1	32
35	Parkinson's Disease: <i>Glucocerebrosidase 1</i> Mutation Severity Is Associated with CSF <i>α</i> -Synuclein Profiles. <i>Movement Disorders</i> , 2020, 35, 495-499.	2.2	32
36	Genomewide Association Studies of <i>LRRK2</i> Modifiers of Parkinson's Disease. <i>Annals of Neurology</i> , 2021, 90, 76-88.	2.8	30

#	ARTICLE	IF	CITATIONS
37	Phenylalanine Effects on Brain Function in Adult Phenylketonuria. <i>Neurology</i> , 2021, 96, e399-e411.	1.5	29
38	Investigation of Autosomal Genetic Sex Differences in Parkinson's Disease. <i>Annals of Neurology</i> , 2021, 90, 35-42.	2.8	29
39	Effect of physical activity on cognitive flexibility, depression and RBD in healthy elderly. <i>Clinical Neurology and Neurosurgery</i> , 2018, 165, 88-93.	0.6	26
40	Mild Parkinsonian Signs in the Elderly – Is There an Association with PD? Crosssectional Findings in 992 Individuals. <i>PLoS ONE</i> , 2014, 9, e92878.	1.1	25
41	Dementia with lewy bodies: <i>GBA1</i> mutations are associated with cerebrospinal fluid alpha-synuclein profile. <i>Movement Disorders</i> , 2019, 34, 1069-1073.	2.2	24
42	<i>EIF4G1</i> is neither a strong nor a common risk factor for Parkinson's disease: evidence from large European cohorts: Table 1. <i>Journal of Medical Genetics</i> , 2015, 52, 37-41.	1.5	23
43	Intraindividual Neurofilament Dynamics in Serum Mark the Conversion to Sporadic Parkinson's Disease. <i>Movement Disorders</i> , 2020, 35, 1233-1238.	2.2	22
44	GBA-associated PD: chances and obstacles for targeted treatment strategies. <i>Journal of Neural Transmission</i> , 2022, 129, 1219-1233.	1.4	22
45	Age and Vascular Burden Determinants of Cortical Hemodynamics Underlying Verbal Fluency. <i>PLoS ONE</i> , 2015, 10, e0138863.	1.1	21
46	Mendelian Randomisation Study of Smoking, Alcohol, and Coffee Drinking in Relation to Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2022, 12, 267-282.	1.5	21
47	Neurodegenerative CSF markers in genetic and sporadic PD: Classification and prediction in a longitudinal study. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1427-1434.	1.1	20
48	Changes in CD163+, CD11b+, and CCR2+ peripheral monocytes relate to Parkinson's disease and cognition. <i>Brain, Behavior, and Immunity</i> , 2022, 101, 182-193.	2.0	20
49	Cognitive impairment in Glucocerebrosidase (GBA)-associated PD: Not primarily associated with cerebrospinal fluid Abeta and Tau profiles. <i>Movement Disorders</i> , 2017, 32, 1780-1783.	2.2	19
50	CSF and Serum Levels of Inflammatory Markers in PD: Sparse Correlation, Sex Differences and Association With Neurodegenerative Biomarkers. <i>Frontiers in Neurology</i> , 2022, 13, 834580.	1.1	17
51	Dermal Phospho-Alpha-Synuclein Deposition in Patients With Parkinson's Disease and Mutation of the Glucocerebrosidase Gene. <i>Frontiers in Neurology</i> , 2018, 9, 1094.	1.1	16
52	Arm swing asymmetry in overground walking. <i>Scientific Reports</i> , 2018, 8, 12803.	1.6	16
53	Analysis of DNM3 and VAMP4 as genetic modifiers of LRRK2 Parkinson's disease. <i>Neurobiology of Aging</i> , 2021, 97, 148.e17-148.e24.	1.5	16
54	Blood and Cerebrospinal Fluid Biomarkers of Inflammation in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2022, 12, S183-S200.	1.5	16

#	ARTICLE	IF	CITATIONS
55	Association between vestibulo-ocular reflex suppression, balance, gait, and fall risk in ageing and neurodegenerative disease: protocol of a one-year prospective follow-up study. <i>BMC Neurology</i> , 2015, 15, 192.	0.8	15
56	Reasons for mild parkinsonian signs – Which constellation may indicate neurodegeneration?. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 126-130.	1.1	15
57	<scp>CSF</scp> Protein Level of Neurotransmitter Secretion, Synaptic Plasticity, and Autophagy in <scp>PD</scp> and <scp>DLB</scp>. <i>Movement Disorders</i> , 2021, 36, 2595-2604.	2.2	15
58	Dairy Intake and Parkinson's Disease: A Mendelian Randomization Study. <i>Movement Disorders</i> , 2022, 37, 857-864.	2.2	15
59	A Neurodegenerative Vascular Burden Index and the Impact on Cognition. <i>Frontiers in Aging Neuroscience</i> , 2014, 6, 161.	1.7	14
60	Prospective longitudinal course of cognition in older subjects with mild parkinsonian signs. <i>Alzheimer's Research and Therapy</i> , 2016, 8, 42.	3.0	14
61	Deterioration of executive dysfunction in elderly with REM sleep behavior disorder (RBD). <i>Neurobiology of Aging</i> , 2018, 70, 242-246.	1.5	14
62	Parkinson's disease: evolution of cognitive impairment and CSF A β ₄₂ profiles in a prospective longitudinal study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 165-170.	0.9	14
63	SNPs in A β clearance proteins. <i>Neurology</i> , 2017, 89, 2335-2340.	1.5	13
64	The longevity gene Klotho and its cerebrospinal fluid protein profiles as a modifier for Parkinson's disease. <i>European Journal of Neurology</i> , 2021, 28, 1557-1565.	1.7	12
65	Polygenic load: Earlier disease onset but similar longitudinal progression in Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 1349-1353.	2.2	10
66	GBA-Associated Synucleinopathies: Prime Candidates for Alpha-Synuclein Targeting Compounds. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 562522.	1.8	10
67	TCS in Monogenic Forms of Parkinson's Disease. <i>International Review of Neurobiology</i> , 2010, 90, 157-164.	0.9	9
68	Clinical characteristics related to worsening of motor function assessed by the Unified Parkinson's Disease Rating Scale in the elderly population. <i>Journal of Neurology</i> , 2015, 262, 451-458.	1.8	6
69	Biallelic Parkin (PARK2) mutations can cause a bvFTD phenotype without clinically relevant parkinsonism. <i>Parkinsonism and Related Disorders</i> , 2018, 55, 145-147.	1.1	6
70	Abnormally reduced frontal cortex activity during Trail-Making-Test in prodromal parkinson's disease – a fNIRS study. <i>Neurobiology of Aging</i> , 2021, 105, 148-158.	1.5	6
71	The Interaction between <scp><i>HLA-DRB1</i></scp> and Smoking in Parkinson's Disease Revisited. <i>Movement Disorders</i> , 2022, 37, 1929-1937.	2.2	4
72	Dual-Task Performance in GBA Parkinson's Disease. <i>Parkinson's Disease</i> , 2017, 2017, 1-6.	0.6	2

#	ARTICLE	IF	CITATIONS
73	REM sleep behaviour disorder (RBD): risk for Parkinsonism and executive dysfunction in elderly. <i>Oncotarget</i> , 2018, 9, 36732-36733.	0.8	2
74	Autonomic Symptoms in Older Adults Are Common and Associated With Health-Related Quality of Life. <i>Frontiers in Neurology</i> , 2021, 12, 757748.	1.1	2